---
title: "Guoyuan Securities (HK) Remains a Buy on InnoCare Pharma Ltd. (9969)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305255802.md"
description: "Guoyuan Securities (HK) analyst maintained a Buy rating on InnoCare Pharma Ltd. yesterday and set a price target of HK$16.81.InnoCare Pharma Ltd. has an analyst consensus of Strong Buy, with a price target consensus of HK$18.74."
datetime: "2026-11-12T05:15:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305255802.md)
  - [en](https://longbridge.com/en/news/305255802.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305255802.md)
generator: "portal-rs"
---

# Guoyuan Securities (HK) Remains a Buy on InnoCare Pharma Ltd. (9969)

Guoyuan Securities (HK) analyst maintained a Buy rating on InnoCare Pharma Ltd. yesterday and set a price target of HK$16.81.

InnoCare Pharma Ltd. has an analyst consensus of Strong Buy, with a price target consensus of HK$18.74.

### Related Stocks

- [09969.HK](https://longbridge.com/en/quote/09969.HK.md)
- [688428.CN](https://longbridge.com/en/quote/688428.CN.md)
- [000728.CN](https://longbridge.com/en/quote/000728.CN.md)

## Related News & Research

- [InnoCare Doses First Patient in Phase I Trial of Cancer Drug ICP-B381 in China](https://longbridge.com/en/news/305175446.md)
- [SDIC Securities Remains a Buy on InnoCare Pharma Ltd. (9969)](https://longbridge.com/en/news/297030913.md)
- [InnoCare Reports 2026 Q3 Results, Sustained Profitability and Accelerating Globalization](https://longbridge.com/en/news/303068907.md)
- [InnoCare Pharma (SEHK:9969) Climbed, What Is Driving Attention Today?](https://longbridge.com/en/news/303497906.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**